Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population
Aurelie Delacretaz, Anais Glatard, Celine Dubath, Mehdi Gholam, Franziska Gamma, Armin von Gunten, Philippe Conus, Chin B Eap
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | WILEY | Published : 2021
Few studies have evaluated the influence of valproate on the deterioration of the lipid profile in psychiatric patients. This observational study aimed to compare the evolution of metabolic parameters in a sample of adult patients starting valproate (n = 39) with a control group (n = 39) of patients starting aripiprazole, a drug associated with a low risk of metabolic deterioration. Data were obtained from a prospective study including psychiatric patients with metabolic parameters monitored during the first year of treatment. During the first month of treatment with valproate (median: 31 days [IQR: 25-36]), mean body mass index increased significantly (from 24.8 kg/m2 at baseline to 25.2 kg..View full abstract
Awarded by Swiss National Research Foundation
This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 320030-120686, 324730-144064 and 320030-173211). The funding sources had no role in the writing of the manuscript or in the decision to submit it for publication.